Roche's Cancer Drug Candidate Shows Positive Results in Late Stage Trial
By Helena Smolak
Late-stage trial data for Roche's cancer drug Gazyva/Gazyvaro showed positive results in patients with kidney inflammation, increasing the likelihood of regulatory approval in Europe and the U.S.
Swiss pharma giant Roche said Thursday that it aims to bring the potential lupus nephritis treatment--which seeks to prevent or delay progression in end-stage kidney disease--to market as soon as possible after a study demonstrated treatment benefits compared to the standard of care.
The experimental drug candidate's late-stage trial showed a complete renal response among patients with lupus nephritis.
The data read-out over 76 weeks also met two key secondary goals--reduced corticosteroid use and improved proteinuric response--that were statistically significant, the company said. The safety profile was in line with the drug's profile and no new safety signals were identified, it said.
Gazyva/Gazyvaro was granted breakthrough therapy designation by FDA in 2019.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
September 26, 2024 01:42 ET (05:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks